Replies to post #107592 on Biotech Values

[jbog]

Dew,

It looks like the final inroad for momenta will be to capture some of the large group contracts once the expire.

What would be standard as to the length of time that Sanofi has these customers tied up?

tia

[Mpower]

Thanks for the clarification. It is also interesting that Sanofi was explicit in asserting their expectation for further erosion in the coming quarters as a result of the new generic competition. This is to some extent shocking, since MNTA/Sandoz control ~half the Lovenox market in the 3Q. How much more are they expecting to lose? Further erosion of SNY's Lovenox is a major positive for MNTA.

[turtlepower]

Re a lovenox authorized generic, the only instance that topic appeared to come up was at around the 28 minute mark. In response to an AG related question Viehbacher appeared to say that SNY doesn't want to tips its hand and then Spek said SNY would be ready when the right scenario occurs, whatever that scenario may be. I agree that he was probably referring to an additional generic entering the market. As long as m-enox maintains a 40-60% market share range there is no logic in introducing an AG.

http://www.thomson-webcast.net/uk/dispatching/?event_id=0c88d7ba71afe501d7b2e25c244be152&portal_id=2ba4dbdbaced91ffe0c73e301ff6ea0e